Document is current

Any future updates will be listed below

Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial

Crossref DOI link: https://doi.org/10.1038/s41467-025-63978-y

Published Online: 2025-10-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark